Literature DB >> 8769129

Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase.

E S Arnér1, J Nordberg, A Holmgren.   

Abstract

Reduction of the antioxidant lipoic acid has been proposed to be catalyzed in vivo by lipoamide dehydrogenase (LipDH) or glutathione reductase (GR). We have found that thioredoxin reductase (TR) from calf thymus, calf liver, human placenta, and rat liver efficiently reduced both lipoic acid and lipoamide with Michaelis-Menten type kinetics in NADPH-dependent reactions. In contrast to LipDH, lipoic acid was reduced almost as efficiently as lipoamide. Under equivalent conditions at 20 degrees C, pH 8.0, mammalian TR reduced lipoic acid by NADPH 15 times more efficiently than the corresponding NADH dependent reduction catalyzed by LipDH (297 min-1 for TR vs. 20.3 min-1 for LipDH). Moreover, TR was 2.5 times faster in reducing lipoic acid with NADPH than in catalyzing the reverse reaction (oxidation of dihydrolipoic acid with NADP+). In contrast, LipDH was only 0.048 times as efficient in the forward reaction as compared to the reverse reaction (using NADH and NAD+). We conclude that all or part of the previously described NADPH-dependent lipoamide dehydrogenase (diaphorase) activities in mammalian systems should be attributed to TR. Our results suggest that in mammalian cells a significant part of the therapeutically important reduction of lipoic acid is catalyzed by thioredoxin reductase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769129     DOI: 10.1006/bbrc.1996.1165

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

Review 1.  Thioredoxin reductase.

Authors:  D Mustacich; G Powis
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

2.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

3.  Uptake and reduction of alpha-lipoic acid by human erythrocytes.

Authors:  James M May; Zhi-chao Qu; Deanna J Nelson
Journal:  Clin Biochem       Date:  2007-07-05       Impact factor: 3.281

4.  Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells.

Authors:  Margareta Berggren; Sivanandane Sittadjody; Zuohe Song; Jean-Louis Samira; Randy Burd; Emmanuelle J Meuillet
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

5.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

6.  Nitric oxide and thioredoxin type 1 modulate the activity of caspase 8 in HepG2 cells.

Authors:  Rajib Sengupta; Timothy R Billiar; Valerian E Kagan; Detcho A Stoyanovsky
Journal:  Biochem Biophys Res Commun       Date:  2009-12-11       Impact factor: 3.575

7.  Assessing the reductive capacity of cells by measuring the recycling of ascorbic and lipoic acids.

Authors:  James M May
Journal:  Methods Mol Biol       Date:  2010

8.  The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.

Authors:  Jennifer D Tibodeau; Linda M Benson; Crescent R Isham; Whyte G Owen; Keith C Bible
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

Review 9.  Thioredoxin glutathione reductase-dependent redox networks in platyhelminth parasites.

Authors:  David L Williams; Mariana Bonilla; Vadim N Gladyshev; Gustavo Salinas
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

10.  JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.

Authors:  Kornelia Edes; Pamela Cassidy; Paul J Shami; Philip J Moos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.